INOVIO PHARMACEUTICALS, INC.
corporate_fare Company Profile
INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for INO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for INO spans 8-K, 10-Q, 424B5, S-3.
Recent high-impact activity:
- Inovio Q2 Loss Narrows to $6M on Warrant Gain; FDA Decision Due Oct 30
- INOVIO Reports Q2 2026 Results; FDA Review of INO-3107 Advances Toward October 30 PDUFA
- INOVIO Q2 2026: Going Concern Doubt, Cash Runway to Q1 2027, FDA Decision Looms
- INOVIO Prices $20M Offering at $0.95, Deepening Dilution Fears
- Inovio Flags $36.7M in Preliminary Q2 Cash as Liquidity Fears Mount
Financial Snapshot
Short Interest & Short Volume
6.54 days to coverFINRA reported short interest of 19,921,776 shares in INO as of the September 15, 2026 settlement, a 3.5% increase from the prior period — about 6.5 days to cover at its recent average daily volume. On October 2, 2026, 35.6% of INO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for INO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-30.
Offering Terms Finalized · Use of Proceeds
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →